Get the Stockscreener App
97.46
0.40%
-0.39
After Hours:
98.20
0.74
+0.76%
Insmed Inc stock is traded at $97.46, with a volume of 3.79M.
It is down -0.40% in the last 24 hours and down -10.70% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$97.85
Open:
$98.85
24h Volume:
3.79M
Relative Volume:
1.18
Market Cap:
$21.12B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-16.97
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
+3.49%
1M Performance:
-10.70%
6M Performance:
-50.51%
1Y Performance:
-1.29%
1-Day Range:
$97.03
$100.17
1-Week Range:
$90.39
$100.17
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
97.46 | 21.21B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed (INSM) Sees Price Target Reduction Amid Market Sentiment Shift - GuruFocus
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Monashee Investment Management LLC Acquires Shares of 50,000 Insmed, Inc. $INSM - MarketBeat
A Blueprint For Addressing Underserved Patient Populations - Clinical Leader
Nasdaq-100 Index® June 2026 Quarterly Changes - GlobeNewswire Inc.
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $214 - Moomoo
Insmed stock hits 52-week low at 90.85 USD By Investing.com - Investing.com Nigeria
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Insmed slides 7.9% as risk-off tape collides with pipeline-focused positioning ahead of TPIP data - Quiver Quantitative
[Form 4] INSMED Inc Insider Trading Activity - Stock Titan
Insmed stock hits 52-week low at 90.85 USD - Investing.com
Stock Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook - Investing.com UK
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook By Investing.com - Investing.com Australia
GW&K Investment Management LLC Reduces Position in Insmed, Inc. $INSM - MarketBeat
Axiom Investors LLC DE Has $44.53 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): pipeline update and growth story in rare diseases - AD HOC NEWS
INSM: Brensocatib’s stellar launch and expanding pipeline set the stage for sustained growth - TradingView
Insmed Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
INSM Maintained by JP Morgan -- Price Target Lowered to $179 - GuruFocus
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline - GuruFocus
William Lewis files Form 144 — INSM insider sale notice (INSM) - Stock Titan
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed Is Maintained at Overweight by JP Morgan - Moomoo
JPMorgan Chase & Co. Cuts Insmed (NASDAQ:INSM) Price Target to $179.00 - MarketBeat
Is Insmed (INSM) The Best Healthcare Stock to Buy Now? - Yahoo Finance
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
ING Groep NV Sells 250,555 Shares of Insmed, Inc. $INSM - MarketBeat
Fiera Capital Corp Raises Stock Position in Insmed, Inc. $INSM - MarketBeat
Clearbridge Investments LLC Has $142.54 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Daiwa Securities Group Inc. Acquires 34,648 Shares of Insmed, Inc. $INSM - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases Shares of 50,500 Insmed, Inc. $INSM - MarketBeat
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Operating income of Insmed Incorporated – XETR:IM8N - TradingView
Return on equity % of Insmed Incorporated – XETR:IM8N - TradingView
Taxes of Insmed Incorporated – XETR:IM8N - TradingView
Insmed Incorporated Balance Sheet – XETR:IM8N - TradingView
Is Insmed's (INSM) Brensocatib Momentum Quietly Reframing Its Respiratory Growth Narrative? - Yahoo Finance
Harvest Fund Management Co. Ltd Acquires 14,454 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Lowered to $195 - GuruFocus
INSM: Director Martina Flammer reports multiple Rule 144 sales (INSM) - Stock Titan
Insmed Chair, CEO Sold Shares Worth Over $777K - TradingView
INSMED (INSM) COO sells 2,370 shares to cover RSU tax withholding - Stock Titan
Insmed (NASDAQ: INSM) CFO sells 2,404 shares to cover RSU taxes - Stock Titan
INSMED (INSM) legal chief sells 2,159 shares to cover RSU tax - Stock Titan
Insmed (INSM) CMO sells 4,424 shares for tax withholding under plan - Stock Titan
Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says - Moomoo
RBC Capital Adjusts Insmed Price Target to $195 From $205, Maintains Outperform Rating - Moomoo
RBC Capital lowers Insmed stock price target to $195 on model refinement - Investing.com UK
Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
RBC Capital lowers Insmed stock price target to $195 on model refinement By Investing.com - Investing.com South Africa
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):